Research letterTofacitinib 2% ointment, a topical Janus kinase inhibitor, for the treatment of alopecia areata: A pilot study of 10 patients
References (5)
- et al.
Tofacitinib for the treatment of severe alopecia areata and variants: a study of 90 patients
J Am Acad Dermatol
(2017) - et al.
Topical Janus kinase inhibitors for the treatment of pediatric alopecia areata
J Am Acad Dermatol
(2017)
There are more references available in the full text version of this article.
Cited by (0)
Funding sources: Dr Liu received funding support from the Yale University Medical Student Research Fellowship. Dr King received funding support from The Ranjini and Ajay Poddar Resource Fund for Dermatologic Diseases Research.
Conflicts of interest: Dr King has served on advisory boards or as consultant for Aclaris Therapeutics Inc, Celgene, Concert Pharmaceuticals Inc, Eli Lilly and Company, Pfizer Inc, Regeneron Pharmaceuticals, and Roivant Sciences Ltd. Other authors have no conflicts of interest to report.
© 2017 by the American Academy of Dermatology, Inc.